Previous 10 | Next 10 |
home / stock / crpof / crpof news
- Second human trial to be conducted as part of a long-term Master Service Agreement with MHI - Phase 1 study with Ceapro’s pharmaceutical grade avenanthramide to be coordinated by MHI’s Montreal Health Innovations Coordinating Center (MHICC) and led by Dr. Jean-Clau...
Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...
Every time there is a major disease outbreak, one of the first questions scientists and the public ask is: “Where did this come from?” In order to predict and prevent future pandemics like COVID-19, researchers need to find the origin of the viruses that cause them. This is not a...
EDMONTON, Alberta, June 01, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”) , a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and co...
Ceapro (CRPOF) announces the completion of patient enrollment in its comparison study evaluating high-medium molecular weight beta glucan as a stand-alone or add-on therapy to statins in subjects with hyperlipidemia, a condition in which high levels of fat build up in the blood.The compa...
– Clinical study evaluating the well-known health claims of beta glucan and its potentially beneficial approach for patients to lower plasma cholesterol – – Study conducted in collaboration with the Montreal Heart Institute and led by MHI’s Montreal H...
– Maintained production operations during COVID-19 pandemic, providing customers essential products while ensuring the health and safety of Company’s employees – – Increased R&D investments for the development of innovative delivery systems and fo...
Ceapro (CRPOF): Q4 Net loss of $539KRevenue of $2.71M (-27.2% Y/Y)Press Release For further details see: Ceapro reports Q4 results
Maintained production operations during COVID-19 pandemic, providing customers with essential products and completing integration of manufacturing site , while ensuring the health and safety of employees Substantially increased sales, net profits and cash generated from ...
The FDA approval process for vaccines, therapeutics, and other pharmaceuticals was on the nightly news through late 2020. Investors and non-investors alike developed some understanding of that FDA timeline. Medical device clearance is less understood yet critical for investors looking to benef...
News, Short Squeeze, Breakout and More Instantly...
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, ...
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology – Q1 2024 sales of $2,800,000 vs $3,500,0...
Faraday Future Intelligent Electric Inc. (FFIE) is expected to report for Q1 2024 D-Market Electronic Services & Trading (HEPS) is expected to report for Q1 2024 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2024 Check-Cap Ltd. (CHEK) is expected to report $-0.17 for ...